A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Clinical trial NCT07218003 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT07218003
Sponsor: Rondo Therapeutics
Status: ENROLLING_BY_INVITATION
Phase: Phase 1
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer Cervical Cancer Head and Neck Squamous Cell Cancer Triple Negative Breast Cancer (TNBC)Urothelial Carcinoma Bladder Gastroesophageal Junction (GEJ) Adenocarcinoma Esophageal Squamous Cell Cancer Gastric Cancer Cancer Solid Tumors (Phase 1)

Start date: 2025-11-17
Primary completion: 2029-02-28
Enrollment: 149

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.